Last reviewed · How we verify
NCT06108063
Mitigation of Arthrofibrosis After Total Knee Arthroplasty Using Losartan
Phase 1, PHASE2 trial testing Losartan in Knee Arthroplasty, Total in 120 participants. Currently enrolling.
30 June 2027
Quick facts
| Lead sponsor | Steadman Philippon Research Institute |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | prevention |
| Enrollment | 120 |
| Start date | 6 March 2024 |
| Primary completion | 30 June 2027 |
| Estimated completion | 30 June 2027 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Losartan (losartan) — full drug profile →
- Placebo - Losartan — full drug profile →
Conditions studied
- Knee Arthroplasty, Total — all drugs for Knee Arthroplasty, Total →
Sponsor
Steadman Philippon Research Institute
Who can join
18 and older, any sex, with Knee Arthroplasty, Total. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to evaluate the efficacy of Losartan use post-operatively for reducing or preventing the development of arthrofibrosis and the associated adverse impacts on clinical outcomes.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06108063
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Losartan
Trials testing the same drug.
- NCT06491940 — Comparison of the Role of Losartan Alone vs Hydrochlorothiazide Plus Losartan · NA · not yet recruiting
- NCT06333522 — Losartan Use to Mitigate Arthrofibrosis Following Total Joint Arthroplasty · Phase 4 · withdrawn
- NCT06150560 — A Study of Angiotensin-II Receptor Blocker on Cardiovascular Remodeling (VALUE Trial) · Phase 3 · recruiting
- NCT06329050 — The Effects of Losartan on Attention Control: An Eye-tracking Study · NA · recruiting
- NCT06329076 — Losartan Modulates Neural Responses to Looming Visual Stimuli: An Eye-tracking Study · NA · recruiting
Other recruiting trials for Knee Arthroplasty, Total
Currently open trials in the same condition.
- NCT07526831 — Comparison of the Analgesic Efficacy of Adductor Canal Block and Combined Adductor Canal Block Plus IPACK Block in Knee · recruiting
- NCT07425457 — Cryoneurolysis Prior to Total Knee Arthroplasty (CRYO-TKA Trial) · NA · recruiting
- NCT07256548 — Machine Learning for Predicting Spinal Anesthesia Duration · recruiting
- NCT07489963 — Functional Impact at 12 Months Post-op of Posterior Cruciate Ligament Conservation During Robotic-assisted Surgery (MAKO · NA · recruiting
- NCT07089251 — The Perioperative Outcome of Epinephrine Infusion and Tranexamic Acid in Knee Arthroplasty Surgery · Phase 4 · recruiting
Other Steadman Philippon Research Institute trials
Trials by the same sponsor.
- NCT07397806 — Home-Based Leg Dexterity Trainer for Management of Knee Osteoarthritis · NA · recruiting
- NCT05025956 — Senolytic Agent Improve the Benefit of Platelet-Rich Plasma and Losartan · Phase 1, PHASE2 · active not recruiting
- NCT04815902 — Use of Senolytic and Anti-Fibrotic Agents to Improve the Beneficial Effect of Bone Marrow Stem Cells for Osteoarthritis · Phase 1, PHASE2 · active not recruiting
- NCT04212650 — Losartan to Improve Hip Microfracture · Phase 1, PHASE2 · terminated
- NCT04210986 — Senolytic Drugs Attenuate Osteoarthritis-Related Articular Cartilage Degeneration: A Clinical Trial · Phase 1, PHASE2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06108063 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Steadman Philippon Research Institute
- Last refreshed: 12 March 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06108063.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing